372 related articles for article (PubMed ID: 18308250)
1. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.
Pearson AD; Pinkerton CR; Lewis IJ; Imeson J; Ellershaw C; Machin D; ;
Lancet Oncol; 2008 Mar; 9(3):247-56. PubMed ID: 18308250
[TBL] [Abstract][Full Text] [Related]
2. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
[TBL] [Abstract][Full Text] [Related]
3. Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.
Peinemann F; Tushabe DA; van Dalen EC; Berthold F
Cochrane Database Syst Rev; 2015 May; 2015(5):CD010774. PubMed ID: 25989478
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
[TBL] [Abstract][Full Text] [Related]
5. The evaluation of induction chemotherapy regimens for high-risk neuroblastoma in South African children
Van Heerden J; Geel J; Hendricks M; Wouters K; Büchner A; Naidu G; Hadley GP; Du Plessis J; Van Emmenes B; Van Zyl A; Vermeulen J; Kruger M
Pediatr Hematol Oncol; 2020 May; 37(4):300-313. PubMed ID: 32075464
[TBL] [Abstract][Full Text] [Related]
6. OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age.
Tweddle DA; Pinkerton CR; Lewis IJ; Ellershaw C; Cole M; Pearson AD
Med Pediatr Oncol; 2001 Jan; 36(1):239-42. PubMed ID: 11464894
[TBL] [Abstract][Full Text] [Related]
7. Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.
Garaventa A; Poetschger U; Valteau-Couanet D; Luksch R; Castel V; Elliott M; Ash S; Chan GCF; Laureys G; Beck-Popovic M; Vettenranta K; Balwierz W; Schroeder H; Owens C; Cesen M; Papadakis V; Trahair T; Schleiermacher G; Ambros P; Sorrentino S; Pearson ADJ; Ladenstein RL
J Clin Oncol; 2021 Aug; 39(23):2552-2563. PubMed ID: 34152804
[TBL] [Abstract][Full Text] [Related]
8. Rapid COJEC Induction Therapy for High-risk Neuroblastoma Patients - Cochrane Review.
Peinemann F; van Dalen EC; Berthold F
Klin Padiatr; 2016 Apr; 228(3):130-4. PubMed ID: 27043079
[TBL] [Abstract][Full Text] [Related]
9. Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial.
Moreno L; Vaidya SJ; Schrey D; Pinkerton CR; Lewis IJ; Kearns PR; Machin D; Pearson ADJ;
Pediatr Blood Cancer; 2019 Apr; 66(4):e27565. PubMed ID: 30516328
[TBL] [Abstract][Full Text] [Related]
10. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
[TBL] [Abstract][Full Text] [Related]
11. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.
Pritchard J; Cotterill SJ; Germond SM; Imeson J; de Kraker J; Jones DR
Pediatr Blood Cancer; 2005 Apr; 44(4):348-57. PubMed ID: 15546135
[TBL] [Abstract][Full Text] [Related]
12. Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study.
Ladenstein R; Valteau-Couanet D; Brock P; Yaniv I; Castel V; Laureys G; Malis J; Papadakis V; Lacerda A; Ruud E; Kogner P; Garami M; Balwierz W; Schroeder H; Beck-Popovic M; Schreier G; Machin D; Pötschger U; Pearson A
J Clin Oncol; 2010 Jul; 28(21):3516-24. PubMed ID: 20567002
[TBL] [Abstract][Full Text] [Related]
13. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
[TBL] [Abstract][Full Text] [Related]
14. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.
Berthold F; Boos J; Burdach S; Erttmann R; Henze G; Hermann J; Klingebiel T; Kremens B; Schilling FH; Schrappe M; Simon T; Hero B
Lancet Oncol; 2005 Sep; 6(9):649-58. PubMed ID: 16129365
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
16. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
Park JR; Kreissman SG; London WB; Naranjo A; Cohn SL; Hogarty MD; Tenney SC; Haas-Kogan D; Shaw PJ; Kraveka JM; Roberts SS; Geiger JD; Doski JJ; Voss SD; Maris JM; Grupp SA; Diller L
JAMA; 2019 Aug; 322(8):746-755. PubMed ID: 31454045
[TBL] [Abstract][Full Text] [Related]
17. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
De Ioris MA; Castellano A; Ilari I; Garganese MC; Natali G; Inserra A; De Vito R; Ravà L; De Pasquale MD; Locatelli F; Donfrancesco A; Jenkner A
Eur J Cancer; 2011 Mar; 47(4):572-8. PubMed ID: 21112775
[TBL] [Abstract][Full Text] [Related]
18. Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR.
Berthold F; Faldum A; Ernst A; Boos J; Dilloo D; Eggert A; Fischer M; Frühwald M; Henze G; Klingebiel T; Kratz C; Kremens B; Krug B; Leuschner I; Schmidt M; Schmidt R; Schumacher-Kuckelkorn R; von Schweinitz D; Schilling FH; Theissen J; Volland R; Hero B; Simon T
Ann Oncol; 2020 Mar; 31(3):422-429. PubMed ID: 32067684
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
20. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.
Valteau-Couanet D; Michon J; Boneu A; Rodary C; Perel Y; Bergeron C; Rubie H; Coze C; Plantaz D; Bernard F; Chastagner P; Bouzy J; Hartmann O
J Clin Oncol; 2005 Jan; 23(3):532-40. PubMed ID: 15659499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
